A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

This study is testing whether adding the immunotherapy drug sintilimab (a PD-1 inhibitor) to standard chemotherapy before and during radiation therapy improves outcomes in people with locally advanced, inoperable esophageal squamous cell cancer. **You may be eligible if...** - You are between 20 and 75 years old - You have confirmed esophageal squamous cell carcinoma in the chest that cannot be removed by surgery - Your cancer has not spread to distant organs - You have not received any prior treatment for esophageal cancer - You are in good physical condition (ECOG 0-1) with life expectancy of at least 6 months - You have at least one measurable tumor **You may NOT be eligible if...** - You have received prior chemotherapy, radiation, or immunotherapy for esophageal cancer - Your cancer has spread to distant organs - You have conditions that make immunotherapy or chemotherapy unsafe Talk to your doctor to see if this trial is right for you.